News Archive Take a trip down Theragnostics memory lane with our news archive below Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021Theragnostics Strengthens Board of Directors with Key AppointmentsAugust 4, 2021Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020Theragnostics attending PSMA Masterclass – LondonMarch 5, 2020Theragnostics attending JPM in San FranciscoJanuary 13, 2020Theragnostics Expands Team with Significant AppointmentsJanuary 10, 2020Theragnostics strengthens leadership team with two key appointmentsNovember 13, 2019Theragnostics CEO Greg Mullen presenting at Targeted Radiopharmaceuticals SummitJune 12, 2019Is it June already?! – Meet us @ SNMMI ’19June 6, 2019Theragnostics Ltd Expands Oncology Portfolio with Licensing of radioPARP InhibitorFebruary 28, 2019Theragnostics will be at the Theranostics World Congress 2019February 20, 2019GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer StudyOctober 2, 2019Theragnostics will be @ EANM ’19 – Booth #4September 30, 2019THERAGNOSTICS SIGNS AGREEMENT WITH ASTRAZENECASeptember 5, 2019Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021Theragnostics Strengthens Board of Directors with Key AppointmentsAugust 4, 2021Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021Theragnostics Strengthens Board of Directors with Key AppointmentsAugust 4, 2021Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021Developing radionuclide PARP inhibitors – MedNous ArticleNovember 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research ProgrammeJune 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership RecognitionMay 7, 2020
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021
Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancerOctober 9, 2019
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021
Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET RadiopharmaceuticalsSeptember 22, 2021
Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET ImagingFebruary 17, 2021
Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare ConferenceNovember 10, 2020
Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer DiagnosticsSeptember 9, 2020
